指南与共识心胸血管麻醉术前评估与围术期医学

欧洲心胸血管外科围术期静脉血栓栓塞预防指南

European guidelines on perioperative venous thromboembolism prophylaxis: Cardiovascular and thoracic surgery.
指南 / 共识 · Eur J Anaesthesiol · 2018-01-01

该指南针对心脏、胸科及血管外科患者,指出现有VTE预测模型未在该人群验证。建议心脏手术和腹主动脉瘤修复术后止血满意即启动药物预防联合间歇充气加压(IPC);胸科低危(无癌症)用IPC,高危(原发或转移癌)用药物预防联合IPC。

要点

  • 心脏手术患者存在≥1项危险因素(年龄>70岁、输血>4U、机械通气>24h、术后并发症)视为VTE高危。
  • 心脏手术和腹主动脉瘤修复术止血满意后即启药物预防联合IPC(Grade 2C)。
  • 胸科无癌症者低危用IPC(Grade 2C);原发或转移癌者高危用药物预防联合IPC(Grade 2B)。

核心结论

  • 心脏手术VTE高危患者止血满意后建议药物预防联合IPC(Grade 2C)。
  • 腹主动脉瘤修复术尤其开放手术VTE和出血风险均高,止血满意后建议药物预防(Grade 2C)。
  • 胸科无癌症低危用IPC(Grade 2C),原发或转移癌高危用药物预防联合IPC(Grade 2B)。

研究设计与样本

  • 欧洲麻醉学杂志发布的围术期VTE预防指南,针对心血管和胸科手术部分。
  • 基于现有证据制定推荐,未在 cardiothoracic 和血管手术人群验证VTE预测模型。

主要发现

  • 心脏手术患者存在年龄>70岁、输血>4U、机械通气>24h或术后并发症之一即为VTE高危。
  • 腹主动脉瘤修复术尤其开放手术VTE风险高且出血风险高。
  • 胸科无癌症患者可视为VTE低危,原发或转移癌患者为VTE高危。

关键数值与推荐

  • 心脏手术高危:年龄>70岁、输血>4U红细胞/新鲜冰冻血浆/冷沉淀、机械通气>24h、术后并发症(如急性肾损伤、感染/脓毒症、神经系统并发症)。
  • 心脏手术:止血满意后药物预防联合IPC(Grade 2C)。
  • 腹主动脉瘤修复术:止血满意后药物预防(Grade 2C)。
  • 胸科低危(无癌症):IPC(Grade 2C);高危(原发或转移癌):药物预防联合IPC(Grade 2B)。

临床怎么用

  • 心脏手术患者评估上述危险因素,止血满意后启动药物预防并联合IPC。
  • 腹主动脉瘤修复术尤其开放手术,止血满意后启动药物预防。
  • 胸科手术区分有无癌症:无癌症用IPC,癌症患者用药物预防联合IPC。

局限性

  • 现有VTE预测模型未在心脏、胸科和血管手术患者中设计并验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

: None of the predictive models for venous thromboembolism (VTE) prophylaxis have been designed for and validated in patients undergoing cardiothoracic and vascular surgery. The presence of one or more risk factors [age over 70 years old, transfusion of more than 4 U of red blood cells/fresh frozen plasma/cryoprecipitate, mechanical ventilation lasting more than 24 h, postoperative complication (e.g. acute kidney injury, infection/sepsis, neurological complication)] should place the cardiac population at high risk for VTE. In this context, we suggest the use of pharmacological prophylaxis as soon as satisfactory haemostasis has been achieved, in addition to intermittent pneumatic compression (IPC) (Grade 2C). In patients undergoing abdominal aortic aneurysm repair, particularly when an open surgical approach is used, the risk for VTE is high and the bleeding risk is high. In this context, we suggest the use of pharmacological prophylaxis as soon as satisfactory haemostasis is achieved (Grade 2C). Patients undergoing thoracic surgery in the absence of cancer could be considered at low risk for VTE. Patients undergoing thoracic surgery with a diagnosis of primary or metastatic cancer should be considered at high risk for VTE. In low-risk patients, we suggest the use of mechanical prophylaxis using IPC (Grade 2C). In high-risk patients, we suggest the use of pharmacological prophylaxis in addition to IPC (Grade 2B).

来源:Eur J Anaesthesiol,查看原文。版权归原作者所有。

引用

  1. Ahmed AB, Koster A, Lance M, et al. European guidelines on perioperative venous thromboembolism prophylaxis: Cardiovascular and thoracic surgery. Eur J Anaesthesiol. 2018. PMID: 29112541. doi:10.1097/EJA.0000000000000708

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。